Clinical trials: Brain Infarction
Stroke
Autoimmune Phenomena After Acute Stroke
The damage of the brain parenchyma, as well as the stroke-induced dysfunction of the blood-brain-barrier can make previously hidden CNS antigens "visible", and can thus lead to the development of autoimmune mechanisms.
- Trial name
- ARIMIS (NCT01082783)
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Acute Stroke
Cytoflavin in Combination With Reperfusion in Stroke Patients
Evaluation of the efficacy and safety of Cytoflavin®, solution for intravenous administration, (OOO NTFF POLYSAN, Russia) for 10 days, patients with cerebral infarction who receive reperfusion therapy, with the start of treatment…
- Trial name
- NCT05297851
- Testing
- Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin), Control
- Where
- 7 sites in Russia
- Volunteers
- 200 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Major Cardiovascular Event, Established Atherosclerotic Cardiovascular Disease
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
The primary objective of the study is to evaluate real-world effectiveness of treatment with Repatha® in combination with SOC, compared with SOC alone, on the risk for cardiovascular (CV) death, myocardial infarction (MI)…
- Trial name
- NCT06295679
- Where
- 90 sites in China
- Volunteers
- 7,000 people
- Sponsor
- Amgen
Stroke
Akershus Early Mobilisation in Stroke Study
Treatment in stroke units compared with treatment in general medical wards reduces the odds of being dead or disabled. Little is known about which components of acute stroke care that is responsible for this benefit.
- Trial name
- AKEMIS (NCT00832351)
- Testing
- Mobilisation
- Where
- Norway
- Volunteers
- 65 people
- Sponsor
- University Hospital, Akershus
Cardiovascular Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
Part A of this study is a Phase 1, First-in-human (FiH), randomized, single-blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD3366 following single…
- Trial name
- NCT04588727
- Testing
- AZD3366, Ticagrelor, acetylsalicylic acid (ASA)
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Carotid Artery Disease, Stroke
Natural History of Carotid Atherosclerosis
A prospective study of 700 patients with coronary artery disease will undergo non invasive evaluation of their carotid arteries by ultrasound and microwave radiometry.
- Conditions
- Carotid Artery Disease, Stroke, Myocardial Infarction, Angina Pectoris
- Trial name
- NCT01521351
- Where
- Greece
- Volunteers
- 700 people
- Sponsor
- National and Kapodistrian University of Athens
Type 2 Diabetes, Stroke
The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men
Type 2 diabetes mellitus, T2D is a disease characterized by an immense growing prevalence world wide with an increased risk of myocardial infarction and stroke.
- Conditions
- Type 2 Diabetes, Stroke, Myocardial Infarction
- Trial name
- NCT00256256
- Testing
- glucagon-like-peptide-1
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Stroke, Myocardial Infarction
Impact of a Therapeutic Education Program of Patient on the Evolution of the Cardiovascular Chronic Disease
The Exploration Center for Prevention and Treatment of Atherosclerosis (CEPTA, Bordeaux Hospital University) showed that following myocardial infarct (MI) or ischemic stroke (TIA or stroke), the global management (medical and…
- Trial name
- ETHEPAT (NCT02819791)
- Testing
- Optimized conventional therapy alone, Optimized conventional therapy with therapeutic education
- Where
- France
- Volunteers
- 202 people
- Sponsor
- University Hospital, Bordeaux
Cadasil
CERebrolysin In CADASIL
The objective of this trial is the global risk-benefit assessment of Cerebrolysin as compared to Placebo in patients with genetically proven CADASIL.
- Trial name
- CERICA (NCT05755997)
- Testing
- Cerebrolysin, 0.9 % NaCl
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- Ever Neuro Pharma GmbH
Ischemic Stroke
DIRECT-SAFE: A Randomized Controlled Trial of DIRECT Endovascular Clot Retrieval Versus Standard Bridging Thrombolysis With Endovascular Clot Retrieval
The study will be a multicentre, prospective, randomized, open label, blinded endpoint (PROBE) phase 3 trial (2 arm with 1:1 randomization) in ischemic stroke patients within 4.5 hours of stroke onset.
- Trial name
- NCT03494920
- Testing
- Direct endovascular clot retrieval, Bridging thrombolysis followed by ECR
- Where
- 33 sites in Australia, China and 2 more
- Volunteers
- 295 people
- Sponsor
- Neuroscience Trials Australia
Cerebrovascular Accident, Infarction
Evaluation of Treated and Untreated Stroke
This project will investigate the evolution of treated and untreated stroke in patients recruited from the collaborative brain stroke program between NINDS, CC, and Suburban Hospital.
- Conditions
- Cerebrovascular Accident, Infarction, Ischemia
- Trial name
- NCT00001840
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Diabetes Mellitus, Type 2, Cardiovascular Diseases
The Cardio-Metabolic Clinic
This study aims to investigate whether a Cardio-Metabolic Clinic can protect the cardiovascular health of patients with both diabetes and cardiovascular disease.
- Trial name
- ProtecT-2-D (NCT06203860)
- Testing
- Cardio-Metabolic Clinic
- Where
- Denmark
- Volunteers
- 1,600 people
- Sponsor
- Odense University Hospital
Myocardial Infarction, Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack)
Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
This study aims to gather information to what extent patients follow the treatment regimen of low-dose aspirin for primary and secondary prevention of diseases of the heart and blood vessels.
- Conditions
- Myocardial Infarction, Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack), Unstable Angina, Angina
- Trial name
- PALACE (NCT04097912)
- Testing
- Acetylsalicylic Acid (Aspirin, BAYE4465)
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Dementia, Cognitive Change
MIND Diet to Improve Cognitive Function in Mild Stroke Patients
A 6-month pilot randomized controlled trial designed to test the effect of the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet + usual medical care versus usual medical care on the rate of cognitive change…
- Conditions
- Dementia, Cognitive Change, Stroke, Cerebral Infarction
- Trial name
- MINDICOMS (NCT05921084)
- Testing
- MIND diet intervention, General dietary advice
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhejiang University
Cardiovascular Diseases, Cerebrovascular Accident
Homocyst(e)Ine, Vitamin Status, and CVD Risk
To test the hypotheses that the risk of myocardial infarction and/or stroke is associated with elevated plasma levels of homocysteine, and low plasma levels of folate, vitamins B12 and B6.
- Conditions
- Cardiovascular Diseases, Cerebrovascular Accident, Coronary Disease, Myocardial Infarction
- Trial name
- NCT00005482
- Sponsor
- University of Washington
Cardiovascular Diseases, Heart Diseases
Epidemiology of Insulin Growth Factor (IGF) and Cardiovascular Events
To explore the role of insulin growth factor in cardiovascular disease in older men and women.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Coronary Disease, Myocardial Infarction
- Trial name
- NCT00086424
- Volunteers
- 5,888 people
- Sponsor
- Albert Einstein College of Medicine
Acute Brain Injury Coma, Neurocritical Care
Development and Validation of a Prognostic Model for Neurocritical Patients Using Multimodal Brain Monitoring
This study aims to develop and validate a prognostic model for neurocritical patients using multimodal brain monitoring data. By combining data from various monitoring techniques such as EEG, TCD, and NIRS, this model will help…
- Conditions
- Acute Brain Injury Coma, Neurocritical Care, Cerebral Infarction, Intracranial Hemorrhages
- Trial name
- NCT07115459
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Xiangya Hospital of Central South University
Transcranial Bone Marrow Injection, RK-4
RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction
An open-label, blinded Ib/IIa study investigating the treatment of acute large hemispheric infarction by transcranial bone marrow injection of RK-4 injection For subjects with acute large hemispheric infarction who are…
- Conditions
- Transcranial Bone Marrow Injection, RK-4, Acute Large Hemispheric Infarction, Acute Ischemic Stroke
- Trial name
- NCT07166380
- Testing
- RK-4 injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Neurodawn Pharmaceutical Co., Ltd.
Stroke
The Clinical Trial Research of Stem Cell Transplantation Treats Cerebral
All experimental group patients of 100 patients accept a treatment course stem cell transplantation, including one time stem cell transplantation through intravenous injection way at the 10-21th day of cerebral hemorrhage, and…
- Trial name
- NCT01389453
- Testing
- stem cell transplantation
- Where
- China
- Sponsor
- General Hospital of Chinese Armed Police Forces
Acute Ischemic Stroke
Thrombectomy Revascularization of Intracranial Vessel OcclusioN by Originating From Japan (TRON1-Japan)
To evaluate the efficacy and safety of catheter-based thrombectomy for reperfusion by removing a thrombus in a cerebral blood vessel in patients with acute cerebral infarction (within 8 hours after onset), in whom intravenous…
- Trial name
- TRON1-Japan (NCT02964702)
- Testing
- Thrombectomy Device T-01
- Where
- 13 sites in Japan
- Volunteers
- 50 people
- Sponsor
- JIMRO Co., Ltd.